However, the effect of OPC 41061, the ADH V2 receptor antagonist therapy, in the second protocol of experiments delaying hypertension development shows the relevance of ADH in this phenomenon of hypertonicity and how in the prehypertensive phase of SHR, there is an increased sensitivity to ADH. The gene discussed is AVP; the disease is Hypertension.